Clinical Trial Update: A Safety Study of SGN-CD19A for Leukemia and Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 safety study of SGN-CD19A in patients with Burkitt lymphoma and precursor B-cell lymphoblastic leukemia/lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Precursor B-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• SGN-CD19A

Snippet

Sponsor: Seagen Inc. | Conditions: Burkitt Lymphoma, Precursor B-cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | Status: COMPLETED